The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Control of the Immune Response by Pro-Angiogenic Factors
Open accessAbstract
The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“For example, in colorectal cancer, Pagès and Galon have demonstrated that the absence of pathological signs of early metastatic invasion (vascular emboli, lymphatic invasion, and perineural invasion) was correlated with the presence of effector memory T cells (CD45RO) within the tumor and a better overall and disease-…”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.
Leek, R., Lewis, C. E., Whitehouse, R. M., Greenall, M. J., Clarke, J., & Harris, A. L. (1996) · PubMed · Cited by 1,187
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 810
Li, H., Han, Y., Guo, Q., Zhang, M., & Cao, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.240 · Cited by 777
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 1×
“In another model, overexpression of the histidine-rich glycoprotein (HRG) induces tumor vessels normalization through a down regulation of PlGF, and at the same time, leads to an increase of CD8 lymphocyte infiltration within the tumor (62).”
BackgroundMyeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Self-citationShrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Serafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6621 · Cited by 673
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
Occurrence of malignancy in immunodeficiency diseases: A literature review
Gatti, R. A., & Good, R. A. (1971) · Cancer · doi:10.1002/1097-0142(197107)28:1<89::aid-cncr2820280117>3.0.co;2-q · Cited by 632
Cancer risk after renal transplantation in the nordic countries, 1964–1986
Birkeland, S. A., Storm, H. H., Lamm, L. U., Barlow, L., Blohmé, I., Forsberg, B., Eklund, B., Fjeldborg, O., Friedberg, M., Frödin, L., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600209 · Cited by 613
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Romero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5023.841 · Cited by 505
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 465
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Post-Transplant Malignancy: The Role Of Immunosuppression
Penn, I. (2000) · Drug Safety · doi:10.2165/00002018-200023020-00002 · Cited by 414
CD80 in Immune Suppression by Mouse Ovarian Carcinoma–Associated Gr-1+CD11b+ Myeloid Cells
Yang, R., Cai, Z., Zhang, Y., Yutzy, W. H., Roby, K. F., & Roden, R. B. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3755 · Cited by 343
Lissbrant, I. F., Stattin, P., Wikstrom, P., Damber, J. E., Egevad, L., & Bergh, A. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.3.445 · Cited by 333
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
Self-citationThe effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Fatal Melanoma Transferred in a Donated Kidney 16 Years after Melanoma Surgery
MacKie, R. M., Reid, R., & Junor, B. (2003) · New England Journal of Medicine · doi:10.1056/nejm200302063480620 · Cited by 290
Prognostic value of tumor‐associated macrophage count in human bladder cancer
Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N., & Nomura, Y. (2000) · International Journal of Urology · doi:10.1046/j.1442-2042.2000.00190.x · Cited by 283
Kusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.346 · Cited by 276
Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A. M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111497 · Cited by 250
PlGF: A Multitasking Cytokine with Disease-Restricted Activity
Dewerchin, M., & Carmeliet, P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011056 · Cited by 244
Dikov, M. M., Ohm, J. E., Ray, N., Tchekneva, E. E., Burlison, J., Moghanaki, D., Nadaf, S., & Carbone, D. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.215 · Cited by 244
l-Arginine modulates CD3ζ expression and T cell function in activated human T lymphocytes
Zea, A. H., Rodriguez, P. C., Culotta, K. S., Hernandez, C. P., DeSalvo, J., Ochoa, J. B., Park, H.-J., Zabaleta, J., & Ochoa, A. C. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2005.01.004 · Cited by 233
Huang, Y., Chen, X., Dikov, M. M., Novitskiy, S. V., Mosse, C. A., Yang, L., & Carbone, D. P. (2007) · Blood · doi:10.1182/blood-2007-01-065714 · Cited by 230
Coffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Alfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Self-citationOn immunosurveillance in human cancer.
Thomas, L. (1982) · PubMed Central · Cited by 213
Linde, N., Lederle, W., Depner, S., van Rooijen, N., Gutschalk, C. M., & Mueller, M. M. (2012) · The Journal of Pathology · doi:10.1002/path.3989 · Cited by 195
SARCOMAS IN ORGAN ALLOGRAFT RECIPIENTS1,2
Penn, I. (1995) · Transplantation · doi:10.1097/00007890-199560120-00020 · Cited by 191
Chaux, P., Favre, N., Martin, M., & Martin, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970807)72:4<619::aid-ijc12>3.0.co;2-6 · Cited by 186
Noman, M. Z., Buart, S., Van Pelt, J., Richon, C., Hasmim, M., Leleu, N., Suchorska, W. M., Jalil, A., Lecluse, Y., El Hage, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800854 · Cited by 183
Salvesen, H. B., & Akslen, L. A. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<538::aid-ijc17>3.0.co;2-b · Cited by 182
Transmission of donor melanoma by organ transplantation
Strauss, D. C., & Thomas, J. M. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70024-3 · Cited by 181
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
Prévost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F. M., & Pircher, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2187 · Cited by 172
Ziogas, A. C., Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Terpos, E., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26094 · Cited by 168
Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Ioannou, K., Ziogas, A. C., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.468 · Cited by 167
Bose, A., Taylor, J. L., Alber, S. M., Watkins, S. C., García, J. A., Rini, B. I., Ko, J. S., Cohen, P. A., Finke, J. H., & Storkus, W. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25863 · Cited by 145
Chen, M., Yan, B., Lu, W., Chen, M., Yu, S., Yang, P., & Ann‐Lii, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28362 · Cited by 130
Cao, M., Xu, Y., Youn, J., Cabrera, R., Zhang, X., Gabrilovich, D. I., Nelson, D. R., & Liu, C. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2010.205 · Cited by 129
Farsaci, B., Higgins, J. P., & Hodge, J. W. (2011) · International Journal of Cancer · doi:10.1002/ijc.26219 · Cited by 127
Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K. L., Scuto, A., Jensen, M. C., Deng, J., Forman, S. J., Figlin, R. A., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1293 · Cited by 125
Modulation of Immunity by Antiangiogenic Molecules in Cancer
Terme, M., Colussi, O., Marcheteau, E., Tanchot, C., Tartour, É., & Taïeb, J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/492920 · Cited by 122
Self-citationFischer, T. A., Palmetshofer, A., Gambaryan, S. P., Butt, E., Jassoy, C., Walter, U., Sopper, S., & Lohmann, S. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009781200 · Cited by 85
Lewis, C. E., & Hughes, R. (2007) · Breast Cancer Research · doi:10.1186/bcr1679 · Cited by 68
Lin, Y., Liang, Y., & Chiang, B. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307164 · Cited by 67
Hermans, I. F., Daish, A., Yang, J., Ritchie, D., & Ronchese, F. (1998) · PubMed · Cited by 60
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Bhatia, S., Curti, B. D., Ernstoff, M. S., Gordon, M. S., Heath, E. I., Miller, W. H., Puzanov, I. J., Quinn, D. I., Flaig, T. W., VanVeldhuizen, P. J., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-2 · Cited by 60
Jaini, R., Rayman, P. A., Cohen, P. A., Finke, J. H., & Tuohy, V. K. (2013) · International Journal of Cancer · doi:10.1002/ijc.28488 · Cited by 49
Nagai, H., Mukozu, T., Matsui, D., Kanekawa, T., Kanayama, M., Wakui, N., Momiyama, K., Shinohara, M., Iida, K., Ishii, K., et al. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/607851 · Cited by 32
Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice
Abe, F., Younos, I., Westphal, S. N., Samson, H., Scholar, E. M., Dafferner, A. J., Hoke, T. A., & Talmadge, J. E. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.09.023 · Cited by 29
Research works printed but not linked: 2
- Thomas, 1959, Discussion on Cellular and Humoral Aspects of the Hypersensitive States, 529
- Dall’Oglio, 2011, Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy, Int Braz J Urol, 37, 180, 10.1590/S1677-55382011000200004 · doi:10.1590/s1677-55382011000200004
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0436 · Cited by 986
“These data offer mechanistic insights into the responses to immune-checkpoint blockade, suggesting that response to PD-L1 and PD-1 blockade is not only related to enhanced cytolytic activity, antigen processing, and IFNg pathway components (13, 75), but is also associated with inhibition of fibroblast activation, angi…”
Background
Metadata
- Authors
- Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-04-02
- Volume
- 4
- Pages
- 70-70
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2169435545
- Cited by
- 325
- References
- 100
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.